Shionogi Highlights ALS Biomarker and Digital Health Tools at AAN 2026
Event summary
- Shionogi will present two encore analyses on ALS research at the AAN 2026 Annual Meeting, April 18-22.
- One study assesses neutrophil-to-lymphocyte ratio (NLR) as a potential ALS prognostic biomarker in edaravone-treated patients.
- Another study evaluates smartphone-based telespirometry for at-home ALS monitoring, highlighting the importance of non-invasive ventilation (NIV) use.
- RADICAVA ORS has been used to treat over 22,000 ALS patients in the U.S. since its approval in 2022.
The big picture
Shionogi's presentations at AAN 2026 underscore the growing importance of biomarkers and digital health tools in ALS management. The company's focus on NLR as a prognostic marker and the integration of telespirometry reflect broader industry trends toward personalized medicine and remote patient monitoring. With over 22,000 patients treated with RADICAVA ORS, Shionogi is positioning itself as a key player in the ALS therapeutic landscape, leveraging innovative approaches to address unmet medical needs.
What we're watching
- Biomarker Validation
- Whether NLR can be validated as a reliable prognostic biomarker for ALS, potentially influencing future clinical trial designs and treatment strategies.
- Digital Health Integration
- The pace at which smartphone-based telespirometry and other digital health tools are adopted for ALS monitoring and their impact on clinical outcomes.
- Regulatory Landscape
- How the FDA's Orphan Drug Exclusivity for RADICAVA ORS affects Shionogi's market position and competitive dynamics in the ALS treatment space.
Related topics